Cereno Scientific

Based in Sweden, Cereno Scientific is focused on the development of innovative, effective and safe treatments for people with rare cardiovascular and pulmonary diseases. Lead asset CS1, an HDAC inhibitor that acts as an epigenetic modulator, is currently being investigated in a Phase II clinical trial for the treatment of PAH.

Equities

Equities by Sector

Sectors

Thematics

Latest

JPMorgan European Discovery Trust – The power of small

Rockwood Strategic — Inside the mind of the investor with Richard Staveley of Rockwood Strategic

Metlen Energy & Metals — Edison report on Metlen’s capital markets day: Made of metal, full of energy?

Audiovisual

Latest

Uncovering Trusts – Canadian General Investments (CGI) – A one-stop-shop for investment in Canada

Take on Trusts – June 2025

DUG Technology – executive interview

About Edison

About Edison

Careers

Cereno Scientific (OMX: CRNO-B)

Latest Insights

Cereno Scientific (STO: CRNO-B) enters the FN25 Index

Cereno Scientific — Improved liquidity with latest debt financing

Cereno Scientific — Four-month EAP data support CS1 plans

Cereno Scientific — Firing on all cylinders

Sector

Equity Analyst

Key Management

Cereno Scientific – executive interview

Cereno Scientific — CS1 shines in Phase IIa PAH trial

Cereno Scientific — CS1 granted OMPD, complementing FDA ODD

Cereno Scientific — Pressing clinical assets forward to key inflection

Cereno Scientific — CS1 Phase II results inbound; first dose of CS014

Cereno Scientific — CS014 (second asset) crosses into the clinic

Cereno Scientific — All eyes on Q3 readout after Q1 update

Cereno Scientific — CS014 (thrombosis) progresses towards the clinic

Cereno Scientific – Executive interview with CSO and CMO

Cereno Scientific – executive interview

Cereno Scientific — Differentiated approach in CVD with potential